Vet pharma focus Target opportunities with veterinary biopharmaceutical clients and partners that can leverage KindredBio’s pipeline and partner-ready biologics to expand pet health offerings across cats, dogs, and horses.

Growth through partnerships Explore collaborations with mid to large veterinary distributors and clinics to accelerate adoption of long-acting biologics and IL-31 programs, leveraging KindredBio’s proven half-life extension tech.

Strategic add-ons Position KindredBio’s products as add-on or specialty therapies for premium animal health portfolios, appealing to specialty practices and high-value pet care segments seeking novel therapeutics.

Market expansion signals Capitalize on Elanco acquisition momentum by aligning with larger pharma distributors seeking innovative pet therapeutics; emphasize access to validated targets and human-safety-backed compounds.

Key personnel leverage Engage with KindredBio’s board and leadership network to establish joint development or advisory opportunities with external biotech entities seeking strategic input, pipeline validation, and potential co-development deals.